A pilot study of the role of CD133+ as a cell marker for human haematopoietic stem cells

Not Applicable

Recruiting

• Conditions: Stem cell transplantation; Blood - Haematological diseases; Cancer - Myeloma

• Registration Number: ACTRN12609000590268
• Lead Sponsor: aunceston General Hospital, Pathology Department

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-07-16
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Patients requiring stem cell harvest at the Launceston General Hospital with subsequent stem cell transplantation .

Exclusion Criteria

Patients under 18 years of age. People with intellectual or mental impairment.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To measure stem cells that express CD 133 vial flow cytometry technique.[By completion of stem cell harvest]

Secondary Outcome Measures

Name	Time	Method
To correlate the amount of stem cell harvested with the engraftment kinetics after stem cell transplanatation assessed by regular full blood count daily after transplantation.[Haematological recovery after autologous stem cell transplantation, which is typically range between 2-3 weeks after transplantation.]